Business Update12 Sept 2024, 08:58 pm
DFC Commits US$ 20 Million Long-Term Loan to Panacea Biotec for Hexavalent Vaccine Capacity Expansion
AI Summary
The U.S. International Development Finance Corporation (DFC) has committed a long-term loan of up to US$20 million to Panacea Biotec Ltd. The company has developed a world's first hexavalent vaccine, EasySix®, and is expanding its manufacturing capacity for drug substance antigens. DFC's financing will help Panacea Biotec expedite the expansion and supply the hexavalent vaccine to U.N. agencies for global childhood immunization.
Key Highlights
- DFC commits US$20 million long-term loan to Panacea Biotec
- Panacea Biotec has developed a world's first hexavalent vaccine, EasySix®
- Company is expanding manufacturing capacity for drug substance antigens
- DFC's financing will help expedite the expansion
- Expanded capacity will supply hexavalent vaccine to U.N. agencies globally